Reply to 'Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''.

Bowyer, S; Prithviraj, P; Lorigan, P; Larkin, J; McArthur, G; Atkinson, V; Millward, M; Khou, M; Diem, S; Ramanujam, S; Kong, B; Liniker, E; Guminski, A; Parente, P; Andrews, MC; Parakh, S; Cebon, J; Long, GV; Carlino, MS; Klein, O

View/Open

Published version (122.2Kb)

Publication Date

2017-04

ICR Author

Larkin, James

Marsden,

Author

Bowyer, S

Prithviraj, P

Lorigan, P

Larkin, J

McArthur, G

Atkinson, V

Millward, M

Khou, M

Diem, S

Ramanujam, S

Kong, B

Liniker, E

Guminski, A

Parente, P

Andrews, MC

Parakh, S

Cebon, J

Long, GV

Carlino, MS

Klein, O

Type

Journal Article

Subject

Humans

Melanoma

Skin Neoplasms

CTLA-4 Antigen

Programmed Cell Death 1 Receptor

Ipilimumab

Research team

Melanoma and Kidney Cancer

Language

eng

License start date

2017-04

Citation

British journal of cancer, 2017, 116 (8), pp. e15 - ?

Publications Repository